Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR)
AMD and DR are some of the leading causes of blindness in patients aged 40 years and older.
Age-Related Macular Degeneration
Wet AMD and proliferative DR are characterized by abnormal retinal neovascularization. The current standard of care is intravitreal injection of anti-vascular epithelial growth factor (anti-VEGF). While effective, this is an invasive treatment method that causes patient discomfort and can lead to side effects including infection, bleeding, and retinal detachment. NexThera is developing a non-invasive, peptide-based eye drop therapy for wet AMD (NT-101) and DR (NT-102) as a safer and more convenient solution for patients.
Eye drop therapy
•NexThera’s eye drop therapy delivers PEDF, a peptide that inhibits angiogenesis, into the retina.
•The efficacy of NT-101 was demonstrated to be equivalent or greater than that of EYLEA (an approved treatment for wet AMD that is administered via intravitreal injection) in rodent animal models.